share_log

Alpha Tau Medical Announces First Alpha DaRT Patients Treated In France As Part Of Alpha DaRT Multicenter Skin Cancer Trial

Alpha Tau Medical Announces First Alpha DaRT Patients Treated In France As Part Of Alpha DaRT Multicenter Skin Cancer Trial

作为 Alpha darT 多中心皮肤癌试验的一部分,Alpha Tau Medical 宣布首批在法国接受治疗 Alpha darT 患者
Benzinga Real-time News ·  2022/05/23 09:08

JERUSALEM, May 23, 2022 /PRNewswire/ -- Alpha Tau Medical (NASDAQ:DRTS) (NASDAQ:DRTSW), the developer of the pioneering alpha-radiation cancer therapy Alpha DaRT™, announced today that the first patients in its French multicenter trial for skin cancer were treated with Alpha DaRT, at the Leon Berard Center in Lyon, France by Dr. Pascal Pommier and his team. The Leon Berard Center specializes in radiotherapy for cancer and is affiliated with the National Federation of Cancer Centers in France - UNICANCER Group. Dr. Pommier is the Principal Investigator of the French multicenter study and has more than 20 years of experience in radiation oncology and leading clinical trials.

耶路撒冷,2022年5月23日 /PRNewswire/ — 开创性的α-放射癌疗法Alpha dart™ 的开发者Alpha Tau Medical(纳斯达克股票代码:DRTS)(纳斯达克股票代码:DRTS)今天宣布,帕斯卡尔·波米尔博士及其团队在法国里昂的莱昂·贝拉德中心接受了Alpha dart治疗的法国皮肤癌多中心试验中的第一批患者。莱昂·贝拉德中心专门研究癌症放射治疗,隶属于法国全国癌症中心联合会——UNICANCER集团。Pommier博士是法国多中心研究的首席研究员,在放射肿瘤学和领先的临床试验方面拥有超过20年的经验。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发